| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 67028 |
Intravitreal injection of a pharmacologic agent |
13,477 |
10,435 |
$1.15M |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
14,969 |
11,151 |
$606K |
| 92134 |
|
15,662 |
11,627 |
$231K |
| J9035 |
Injection, bevacizumab, 10 mg |
12,724 |
9,828 |
$174K |
| 67228 |
|
478 |
357 |
$81K |
| 92250 |
|
1,669 |
1,638 |
$33K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,765 |
1,420 |
$10K |
| 92235 |
|
235 |
235 |
$9K |
| 92004 |
Ophthalmological services: medical examination and evaluation, comprehensive, new patient |
147 |
147 |
$3K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
28 |
27 |
$2K |
| 92201 |
|
32 |
29 |
$934.40 |
| 92225 |
|
18 |
15 |
$105.74 |
| 4040F |
|
276 |
223 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
297 |
243 |
$0.00 |
| G9744 |
Patient not eligible due to active diagnosis of hypertension |
157 |
133 |
$0.00 |
| G9974 |
Dilated macular exam performed, including documentation of the presence or absence of macular thickening or geographic atrophy or hemorrhage and the level of macular degeneration severity |
20 |
14 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
65 |
56 |
$0.00 |
| 1036F |
|
290 |
237 |
$0.00 |
| 4177F |
|
106 |
80 |
$0.00 |